AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03321032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolinx Polymer-based zotarolimus-eluting stents
Description: Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
Study NCT03329872 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: data collection about symptoms without any specific clinical or biological intervention
Study NCT05362539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: diagnostic cystoscopy for detection of any bladder lesions
Study NCT05362539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography
Description: Computed tomography for patients to exclude bladder lesions
Study NCT05362539 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA hypermethylation assay
Description: DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
Study NCT05362539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cytology
Description: voided urine cytology for all patients
Study NCT00853047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules; orally 3 times daily.
Study NCT03014869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
Study NCT00820638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myomo e100
Description: use of the myomo e100 in home
Study NCT00853047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
Study NCT00853047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching telotristat etiprate capsules; orally 3 times daily.
Study NCT01905683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (16-20 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
Study NCT03600727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used to offer intraoperative sedation for patients in Propofol group.
Study NCT03600727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
Study NCT03338686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft (FGG)
Description: Free Gingival Graft (FGG) was performed on all study sites in this arm.
Study NCT03338686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft followed by Laser Gingivoplasty
Description: Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
Study NCT00908661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
Description: Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
Study NCT00294567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium channel blockers (amlodipine, azelnidipine)
Description: Drug: amlodipine Drug: azelnidipine
Study NCT01932580 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FLOT (5-fluorouracil, oxaliplatin, docetaxel)
Description: Administration of FLOT chemotherapy before and after surgery
Study NCT02151604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation of hyperpolarized xenon gas
Description: The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
Study NCT03930108 — intervention group
Intervention type: OTHER
Intervention: SOFA score
Description: Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
Study NCT01691092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: All subjects will receive ketamine to induce glutamate release in the brain
Study NCT03899493 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
Study NCT00760175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip (Aventis-Pasteur Canada)
Description: The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
Study NCT02411123 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IDgenetix Neuropsychiatric Test Panel
Description: The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Study NCT00863954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device
Study NCT00691574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: up to 3 mg, daily, for up to 1 year
Study NCT00691574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enviro-light artificial light box
Description: Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
Study NCT01507246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate
Description: Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
Study NCT02760511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content
Study NCT02760511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT04165980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
Study NCT04165980 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
Study NCT04599218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Standard of care
Study NCT04599218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR US Fusion Guided Prostate Biopsy
Description: Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
Study NCT04599218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR/TRUS Fusion Guided Prostate Biopsy
Description: TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
Study NCT03343574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Strengthening Exercise
Description: Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
Study NCT03712852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF+CAF treated patients
Description: Patients will be treated by coronally advanced flap with addition of PRF membrane
Study NCT03712852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTG+ CAF treated patients
Description: Patients will be treated by coronally advanced flap with addition of SCTG graft
Study NCT03712852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF treated patients
Description: Patients will be treated by coronally advanced flap
Study NCT03223194 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT342
Description: AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
Study NCT03235414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Will receive a one time research MRI (MR elastography)
Study NCT01507246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL (bupivacaine liposome injectable suspension)
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study NCT03867253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORY-2001 Low dose
Description: 0.6mg ORY-2001 capsule
Study NCT03867253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORY-2001 High dose
Description: 1.2mg ORY-2001 capsule
Study NCT03867253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT03235414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Will receive a one time blood draw to confirm healthy liver status
Study NCT00133354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex (Anastrozole)
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
Study NCT00133354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
Study NCT00133354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
Study NCT00133354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Growth Hormone
Description: GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
Study NCT04893031 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: 400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
Study NCT02866448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Described in arm
Study NCT02866448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Described in arm
Study NCT02866448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Described in arm
Study NCT02866448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin plus Aspirin
Description: Described in arm
Study NCT01453647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
Study NCT01716169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helicoll
Description: Helicoll Collagen I Wound Dressing
Study NCT01716169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care Dressings
Description: Standard of Care wound dressings (e.g. Vaseline gauze)
Study NCT01600781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)
Description: During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
Study NCT00971321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK2340272A
Description: Two primary intramuscular (IM) injections
Study NCT01328626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
Study NCT01956942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser Trabeculoplasty
Study NCT01956942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Study NCT03017261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSolution One®
Description: Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
Study NCT02513082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sono guided nerve block
Description: Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
Study NCT02513082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono guided nerve block
Description: Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
Study NCT00456612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CyberKnife
Description: Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
Study NCT01160900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty all lesions
Description: treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
Study NCT04114370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
Study NCT04370600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta hydroxybutyrate (BHB) ester
Description: Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
Study NCT04370600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
Study NCT02619656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: Patients were randomized to insufflation with CO2.
Study NCT02619656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambient air insufflation
Description: Patients were randomized to insufflation with ambient air.
Study NCT01135056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIR-Spheres
Description: One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
Study NCT01135056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib tosylate
Description: Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
Study NCT00552058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: certolizumab pegol (CDP870, CZP)
Description: Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Study NCT00552058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
Study NCT01701648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser CO2
Description: Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
Study NCT00795405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to sporting events
Description: Exposure to sporting events
Study NCT00795405 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No exposure to sporting events
Description: No exposure to sporting events
Study NCT03989570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block
Description: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
Study NCT03989570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
Study NCT03989570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: placebo
Study NCT04259242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP
Description: scaling and root planing with ultrasonic scaler and manual instruments
Study NCT03604627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coronal calcium score measurement
Description: A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research.